These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30115425)

  • 1. Comparison of Frequency of Atherosclerotic Cardiovascular and Safety Events With Systolic Blood Pressure <120mm Hg Versus 135-139mm Hg in a Systolic Blood Pressure Intervention Trial Primary Prevention Subgroup.
    Plante TB; Juraschek SP; Miller ER; Appel LJ; Cushman M; Littenberg B
    Am J Cardiol; 2018 Oct; 122(7):1185-1190. PubMed ID: 30115425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Frequency of Atherosclerotic Cardiovascular Disease Events Among Primary and Secondary Prevention Subgroups of the Systolic Blood Pressure Intervention Trial.
    Plante TB; Juraschek SP; Zakai NA; Tracy RP; Cushman M
    Am J Cardiol; 2019 Dec; 124(11):1701-1706. PubMed ID: 31575423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials.
    Basu S; Sussman JB; Rigdon J; Steimle L; Denton BT; Hayward RA
    PLoS Med; 2017 Oct; 14(10):e1002410. PubMed ID: 29040268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial).
    Soliman EZ; Ambrosius WT; Cushman WC; Zhang ZM; Bates JT; Neyra JA; Carson TY; Tamariz L; Ghazi L; Cho ME; Shapiro BP; He J; Fine LJ; Lewis CE;
    Circulation; 2017 Aug; 136(5):440-450. PubMed ID: 28512184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serious Adverse Events Cluster in Participants Experiencing the Primary Composite Cardiovascular Endpoint: A Post Hoc Analysis of the SPRINT Trial.
    Botchway A; Buhnerkempe MG; Prakash V; Al-Akchar M; Adekola B; Flack JM
    Am J Hypertens; 2020 May; 33(6):528-533. PubMed ID: 31930338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coronary Artery Calcium to Guide a Personalized Risk-Based Approach to Initiation and Intensification of Antihypertensive Therapy.
    McEvoy JW; Martin SS; Dardari ZA; Miedema MD; Sandfort V; Yeboah J; Budoff MJ; Goff DC; Psaty BM; Post WS; Nasir K; Blumenthal RS; Blaha MJ
    Circulation; 2017 Jan; 135(2):153-165. PubMed ID: 27881560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalizing the Intensity of Blood Pressure Control: Modeling the Heterogeneity of Risks and Benefits From SPRINT (Systolic Blood Pressure Intervention Trial).
    Patel KK; Arnold SV; Chan PS; Tang Y; Pokharel Y; Jones PG; Spertus JA
    Circ Cardiovasc Qual Outcomes; 2017 Apr; 10(4):. PubMed ID: 28373269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of baseline systolic blood pressure on the relationship between intensive blood pressure control and cardiovascular outcomes in the Systolic Blood Pressure Intervention Trial (SPRINT).
    Sun X; Guo Y; Nie Z; Cheng J; Zhou H; Zhong X; Zhang S; Du Z; Zhuang X; Liao X
    Clin Res Cardiol; 2019 Mar; 108(3):273-281. PubMed ID: 30167807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States: Projections From NHANES (National Health and Nutrition Examination Survey).
    Bress AP; Kramer H; Khatib R; Beddhu S; Cheung AK; Hess R; Bansal VK; Cao G; Yee J; Moran AE; Durazo-Arvizu R; Muntner P; Cooper RS
    Circulation; 2017 Apr; 135(17):1617-1628. PubMed ID: 28193605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is systolic blood pressure below 150 mm Hg an appropriate goal for primary prevention of cardiovascular events among elderly population?
    Mohebi R; Mohebi A; Ghanbarian A; Momenan A; Azizi F; Hadaegh F
    J Am Soc Hypertens; 2014 Jul; 8(7):491-7. PubMed ID: 25064771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Risk of Harm Associated With Intensive Blood Pressure Management Among Patients With Hypertension Who Smoke: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial.
    Scarpa J; Bruzelius E; Doupe P; Le M; Faghmous J; Baum A
    JAMA Netw Open; 2019 Mar; 2(3):e190005. PubMed ID: 30848803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incident Cardiovascular Disease Among Adults With Blood Pressure <140/90 mm Hg.
    Tajeu GS; Booth JN; Colantonio LD; Gottesman RF; Howard G; Lackland DT; O'Brien EC; Oparil S; Ravenell J; Safford MM; Seals SR; Shimbo D; Shea S; Spruill TM; Tanner RM; Muntner P
    Circulation; 2017 Aug; 136(9):798-812. PubMed ID: 28634217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effects of Intensive Blood Pressure Control on Cardiovascular Outcomes Based on 10-Year ASCVD Risk Score: An Analysis of a Clinical Trial.
    Alborzi A; Attar A; Sayadi M; Nouri F
    Cardiol Res Pract; 2021; 2021():6635345. PubMed ID: 34055403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control.
    Beddhu S; Chertow GM; Cheung AK; Cushman WC; Rahman M; Greene T; Wei G; Campbell RC; Conroy M; Freedman BI; Haley W; Horwitz E; Kitzman D; Lash J; Papademetriou V; Pisoni R; Riessen E; Rosendorff C; Watnick SG; Whittle J; Whelton PK;
    Circulation; 2018 Jan; 137(2):134-143. PubMed ID: 29021322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individualising intensive systolic blood pressure reduction in hypertension using computational trial phenomaps and machine learning: a post-hoc analysis of randomised clinical trials.
    Oikonomou EK; Spatz ES; Suchard MA; Khera R
    Lancet Digit Health; 2022 Nov; 4(11):e796-e805. PubMed ID: 36307193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Diuretics in Cardiovascular Events and Mortality in Systolic Blood Pressure Intervention Trial: A Post Hoc Analysis.
    Bansal S; Boucher R; Shen J; Wei G; Chertow GM; Whelton PK; Cushman WC; Cheung AK; Beddhu S;
    Clin J Am Soc Nephrol; 2024 May; 19(5):620-627. PubMed ID: 38262377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Population-Level Blood Pressure Treatment Strategies on Cardiovascular and Cognitive Outcomes.
    Burke JF; Sussman JB; Yaffe K; Hayward RA; Giordani BJ; Galecki AT; Whitney R; Briceño EM; Gross AL; Elkind MSV; Manly JJ; Gottesman RF; Gaskin DJ; Sidney S; Levine DA
    Circ Cardiovasc Qual Outcomes; 2024 Jun; 17(6):e010288. PubMed ID: 38813695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of Prediabetes on the Effects of Intensive Systolic Blood Pressure Control on Kidney Events.
    Rathi N; Whelton PK; Chertow GM; Cushman WC; Cheung AK; Wei G; Boucher R; Kimmel PL; Bress AP; Kramer HJ; Al-Marji C; Greene T; Beddhu S
    Am J Hypertens; 2019 Nov; 32(12):1170-1177. PubMed ID: 31257407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP.
    Buckley LF; Dixon DL; Wohlford GF; Wijesinghe DS; Baker WL; Van Tassell BW
    Diabetes Care; 2017 Dec; 40(12):1733-1738. PubMed ID: 28947569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Intensive Blood Pressure Treatment on Heart Failure Events in the Systolic Blood Pressure Reduction Intervention Trial.
    Upadhya B; Rocco M; Lewis CE; Oparil S; Lovato LC; Cushman WC; Bates JT; Bello NA; Aurigemma G; Fine LJ; Johnson KC; Rodriguez CJ; Raj DS; Rastogi A; Tamariz L; Wiggers A; Kitzman DW;
    Circ Heart Fail; 2017 Apr; 10(4):. PubMed ID: 28364091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.